Kenvue Inc. Reports $456 Million Net Income and $3.955 Billion Revenue for Q2 2026

Kenvue Inc. reported a net income of $456 million for the fiscal three months ended June 28, 2026, reflecting an increase of 8.6% compared to $420 million in the same period last year. The company's revenue for the quarter reached $3.955 billion, a 3.0% rise from $3.839 billion in the prior year. For the first half of the fiscal year, Kenvue's net income was $930 million, up 25.3% from $742 million, while total revenue increased by 3.7% to $7.864 billion from $7.580 billion. The growth in revenue was attributed to favorable pricing actions and strong e-commerce performance across its product segments.

In terms of operational metrics, Kenvue's gross profit for the second quarter was $2.301 billion, with a gross profit margin of 58.2%, down from 58.9% a year earlier. The increase in cost of sales, which rose to $1.654 billion from $1.578 billion, was driven by net input cost inflation and tariffs on imported goods. Selling, general, and administrative expenses were relatively stable, totaling $1.537 billion, a slight increase from $1.504 billion in the previous year. The company also incurred restructuring expenses of $59 million, down from $60 million, as part of its ongoing operational optimization initiatives.

Kenvue's business segments showed varied performance. The Self Care segment generated $1.589 billion in sales, a 2.2% increase, while the Skin Health and Beauty segment saw a 5.1% rise to $1.113 billion. The Essential Health segment reported a modest 2.3% increase in sales to $1.253 billion. The overall segment adjusted operating income for the quarter was $1.013 billion, a slight decrease from $1.027 billion, primarily due to increased expenses and inflationary pressures.

Strategically, Kenvue is in the process of a significant merger with Kimberly-Clark Corporation, which was approved by shareholders in January 2026. Under the terms of the merger agreement, Kenvue shareholders will receive a combination of Kimberly-Clark stock and cash. The transaction is expected to close in the fourth quarter of 2026, pending regulatory approvals. Additionally, Kenvue has been incurring costs related to its separation from Johnson & Johnson, which was completed in August 2023, and is expected to continue for a longer period than initially anticipated.

Looking ahead, Kenvue anticipates continued challenges from macroeconomic factors, including inflation and geopolitical tensions that may impact supply chains. The company is focused on optimizing its operations through its 2026 Restructuring Initiative, which aims to enhance efficiency and reduce complexity. Kenvue's management remains optimistic about its ability to generate positive cash flows and meet its financial obligations, supported by a strong portfolio of consumer health brands.